IRVINE, Calif., Aug. 7, 2013 /PRNewswire/ -- EP Global Communications, Inc. and EPGL Medical (the Company), (OTC-PINK: EPGL) announced today that Company engineers have invented a new device for the purpose of treating serious eye diseases such as macular degeneration and retinitis pigmentosa. The technology emits low intensity pulse ultrasound into the eye for the purpose of regeneration of damaged cells and to possibly arrest the degeneration of existing healthy cells within the macula and the entire retina.

"The technology has proven to be very effective in recent research.  We now have the ability to use MEMS to put the technology into the micro size environment for contact lenses.  This technology will be incorporated into therapeutic contact lenses which will emit a low, safe dose of the ultrasound energy into the eye on a regular basis for the purpose of slowing or arresting the development of macular degeneration, retinitis pigmentosa and other eye disorders," said David T. Markus, PhD.  "We want to pioneer the area of therapeutic contact lenses and we can see a tremendous market size and need going into the future for this technology."

On Monday August 12, 2013 EPGL Medical will introduce three more advanced technological devices which is has invented and is currently developing as prototypes and for FDA clearance in the near future.

Facts on Macular Degeneration

Macular degeneration is the second-highest cause of irreversible blindness in the world.  Macular degeneration is a leading cause of vision loss in Americans 60 years of age and older.  The number of people living with macular degeneration today is similar to that of those who have all types of cancer. As many as 11 million people in the United States have some form of age-related macular degeneration. This number is expected to double to nearly 22 million by 2050.  Macular degeneration is expensive, and will only become more expensive as the population aged 65 and older increases.  Estimates of the global cost of visual impairment due to age-related macular degeneration is US$343 billion, including US$255 billion in direct health care costs.

About EP Global Communications, Inc. / EPGL Medical
EP Global Communications, Inc. is a medical device manufacturer and marketing company with a world-class team of doctors and scientists on board.  The Company is currently marketing its first FDA cleared device with several additional "smart" medical devices under development.  The Company is the owner of the cutting edge technological platform for medical device development called "Topspin."

RELATED LINKS
http://www.epglmed.com

SOURCE EP Global Communications, Inc.